Intermediate risk prostate cancer may be well controlled with brachytherapy alone

September 26, 2016, American Society for Radiation Oncology

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).

NRG Oncology/RTOG 0232 is a phase III, multi-institutional trial conducted at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether adding EBT to transperineal interstitial permanent conveyed an additional benefit in progression free survival (PFS), or control of the cancer growth, at five years following . Brachytherapy is a type of radiation therapy (RT) where radioactive seed implants are inserted directly into a patient's tissue to deliver treatment to the tumor while limiting radiation exposure for surrounding tissue.

Participants in the study included 588 men diagnosed with intermediate risk prostate cancer (i.e., clinical stage T1c-T2b) and enrolled in the trial between 2003 and 2012. Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)—an indication of how aggressively the tumor cells may behave—and the (PSA) level in the patient's blood at the time of diagnosis. Eligible patients for this trial had either a GS between two and six coupled with a PSA between 10 and 20; or a GS of 7 and a PSA less than 10.

Patients were randomized to one of two treatment arms, where 292 patients received brachytherapy alone (the B group) and 287 patients received 45 Gy partial EBT to the pelvic area in addition to brachytherapy (the EBT+B group). Brachytherapy treatment included the use of I-125 or Pd-103 (radioactive Iodine-125 or Palladium-103), prescribed to 110 Gy or 100 Gy respective boost dose for the patients who received brachytherapy plus EBT, and 145 Gy or 125 Gy respective dose for the patients who received brachytherapy alone. EBT was delivered by either intensity-modulated RT or three-dimensional conventional RT.

The primary outcome for this study, PFS, was estimated using the Kaplan-Meier method, and researchers compared the two treatment arms with two-sample binomial testing. Short-term/acute and long-term/late side effects also were measured, including both gastrointestinal (GI) and genitourinary (GU) toxicities. Treatment groups did not differ significantly on any baseline characteristics. The median participant age was 67, two-thirds of patients (67 percent) had stage T1 disease, and 89 percent fell in the GS 7/PSA < 10 group. Median follow-up for all patients was 6.7 years, and 443 patients were eligible for five-year follow-up analyses.

At five years following RT, survival rates for men who received brachytherapy alone were comparable to those who underwent more aggressive radiation treatment. The PFS rate at five years post-treatment was 85 percent for EBT+B patients and 86 percent for B patients (Hazard Ratio, HR, 1.02; futility p = 0.0006).

Although PFS rates were comparable between treatment groups, differences emerged in the rates of more serious side effects. Overall toxicity levels were similar across groups only for acute side effects (i.e., those that occur closely following treatment), with eight percent of patients in each cohort reporting acute grade 3+ side effects. Late severe toxicities were more common for EBT+B patients (12 percent) than for B patients (7 percent), as were severe GU side effects GU (7 vs. 3 percent) and severe GI toxicities (3 vs. 2 percent).

"These findings suggest that many men with intermediate risk prostate cancer can be well managed with seed implant alone and do not require the addition of external beam radiation," said Bradley Prestidge, MD, lead author of the study and Medical Director of the Bon Secours Cancer Institute at DePaul Medical Center in Norfolk, Virginia. "Contrary to expectations, the more aggressive, combined treatment did not result in superior cancer control rates at five years follow-up, indicating that men can achieve a similar survival benefit with fewer late side effects through brachytherapy alone."

Explore further: Permanent radiotherapy implants reduce risk of prostate cancer recurrence after five years

More information: The abstract, "Initial Report of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma Identification and Validation of Intrinsic Subtypes of Prostate Cancer," will be presented in detail during a scientific session at ASTRO's 58th Annual Meeting at 2:15 p.m. Eastern time on Monday, September 26, 2016.

Related Stories

Permanent radiotherapy implants reduce risk of prostate cancer recurrence after five years

April 26, 2015
Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received ...

SBRT offers prostate cancer patients high cancer control and low toxicity in fewer treatments

September 26, 2016
High dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity and excellent cancer control rates, according ...

Extremely hypofractionated radiation therapy shows promising results for intermediate risk prostate cancer patients

September 26, 2016
For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment, which was delivered in seven fractions across two and a ...

African-American men negatively impacted by hormone therapy for treatment of prostate cancer

August 4, 2016
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital found that patients' race significantly affected their longevity by increasing the likelihood of death after receiving ...

SBRT, proton beam therapy use increasing for prostate CA

June 13, 2016
(HealthDay)—For men with prostate cancer, the use of stereotactic body radiotherapy (SBRT) and proton beam therapy increased from 2004 to 2011, according to a study published online May 25 in Cancer.

High-dose radiation therapy as effective as surgery for aggressive prostate cancer

August 8, 2016
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center provides convincing evidence that radiation-based treatments and surgery are equally effective treatments for aggressive prostate cancer. It also suggests ...

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...

Researchers identify ways breast cancer avoids immune system detection

December 18, 2018
Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team ...

Metal chemotherapy drugs boost the impact of immunotherapy in cancer

December 18, 2018
Due to their powerful tumour-killing effect, metal-based chemotherapies are frequently used in cancer treatment. However, it was hitherto assumed that they damaged the immune system, because of their cytotoxic (cell-damaging) ...

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.